Individual Behavior

Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment

2 weeks ago talkbio0Tagged Aggressive Periodontitis, delays, executive survey, Funding, Industry, M&A, Post-Hoc Live, public biotech, Sentiment, United States Food and Drug Administration

biotech sentiment; Post-Hoc Live; 2025 industry outlook; biotech M&A; FDA delays; executive survey; public biotech companies; JP Morgan effect; biotech funding

Endpoints News Launches Industry Sentiment Survey, But No Evidence Yet of a New Biopharma Sentiment Index

3 weeks ago talkbio0Tagged Biopharma, Endpoints, Industry, John Carroll, News [Publication Type], Sentiment, Surveys, trends qualifier

Endpoints News; biopharma; sentiment; survey; industry trends; John Carroll

Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform

2 months ago talkbio0Tagged childhood health, childhood vaccine schedule, Chronic disease, Commission, federal directives, Food Policy, MAHA, Prescription Drug Overuse, public health medicine (field), Robert F. Kennedy Jr., Vaccine Reform

MAHA Commission; chronic disease; vaccine reform; Robert F. Kennedy Jr.; childhood health; food policy; medication overuse; public health; federal directives; childhood vaccine schedule

Cytokinetics Stock Soars After Positive Phase 3 Data as FDA Approval Decision for Aficamten Nears

2 months ago talkbio0Tagged Aficamten, Approved, Cytokinetics, Hypertrophic obstructive cardiomyopathy, PDUFA, Performance, REMS, United States Food and Drug Administration

Cytokinetics; Aficamten; FDA approval; Phase 3 trial; obstructive hypertrophic cardiomyopathy (oHCM); PDUFA date; REMS; stock performance

FDA Lifts Hold on Rocket Pharmaceuticals’ Pivotal Gene Therapy Study at Lower Dose

2 months ago talkbio0Tagged C3 complement inhibitor, Capillary Leak Syndrome, Dosage, gene therapy, Glycogen Storage Disease Type IIb, Individual Adjustment, Phase 2 Clinical Trials, Rocket, RP-A501, Study on Hold, United States Food and Drug Administration

FDA; Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; RP-A501; dose adjustment; C3 complement inhibitor; capillary leak syndrome; patient death; Phase II trial

NIH and HHS Cancel Major mRNA Vaccine Research Funding, Citing Lack of Public Trust

2 months ago talkbio0Tagged BARDA, COVID19 (disease), grant cancellation, Jay Bhattacharya, mRNA Vaccine, NIH Mouse, public trust, research funding, RFK Jr., Vaccination Hesitancy

NIH; mRNA vaccine; public trust; research funding; BARDA; COVID-19; vaccine hesitancy; RFK Jr.; Jay Bhattacharya; grant cancellation

Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns

3 months ago talkbio0Tagged ELEVIDYS, gene therapy, Pauses, Performance, Safety Issues, Sales - occupational activity, United States Food and Drug Administration

Sarepta Therapeutics; Elevidys; Q2 2025; gene therapy; sales performance; FDA; safety issues; shipment pause

Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial

5 months ago talkbio0Tagged AAVS1 gene, ASGCT, Clinical Trials, Dosage, gene therapy, Individual Adjustment, Lymphohistiocytosis, Hemophagocytic, Measures, MECP2 gene, Neurogene, NGN-401, Rett Syndrome, Safety, United States Food and Drug Administration

Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment

Over 500 BMS jobs axed in latest round of NJ cuts

6 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, campus, Drug Industry, employment reduction, Individual Adjustment, Lawrenceville, layoffs, Myers, New Jersey, squibb, WARN, Worker

Bristol Myers Squibb (BMS), Layoffs, New Jersey, Lawrenceville campus, Worker Adjustment and Retraining Notification (WARN), Pharmaceutical industry job cuts, Employment reduction

Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials

9 months ago talkbio0Tagged Antibodies, Clinical Trials, DKK1 gene, LEAP, Malignant neoplasm of stomach, Performance

Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance